Table 1.
Treatment duration, side effects, and sequelae of cCMV patients with GCV/VGCV
| ID | CMV viral load (IU/mL) | Treatment duration | Reduction or suspension of therapy weeks after GCV/VGCV | Side effect | Sensorineural hearing loss | Neuro-development† | ||
|---|---|---|---|---|---|---|---|---|
| Before GCV/VGCV | 6 weeks after GCV/VGCV | at birth | last visit | at 2 years | ||||
| 1 | 51,761 | < LoD* | 6 weeks | None | None | None | None | No delay |
| 2 | 64,649 | < LoD | 6 months | Suspension (4 W, 6–11 W) | Elevated transaminases | Both ears | No change | Mild |
| 3 | 88,674 | < LoD | 6 months | None | None | Right ear | No change | No delay |
| 4 | 150,000 | < LoD | 6 weeks | None | None | None | None | Mild |
| 5 | 87,688 | 5,099 | 3 months | None | None | None | None | No delay |
| 6 | 10,994 | 7,535 | 4 months |
Suspension (3 W, 9–11 W) Reduction (4–8 W) |
Neutropenia | None | None | Mild |
| 7 | 116,600 | 31,975 | 6 months | Suspension (9–10, 12–17 W) reduction (4–8 W) | Neutropenia | None | None | Mild |
| 8 | 271,309 | 280,000 | 3 months | None | None | None | None | Mild |
| 9 | 18,445 | 1250 | 6 weeks | None | None | Both ears | No change | Mild |
| 10 | N.A§ | 2149 | 6 weeks | None | None | Both ears | No change | Mild |
| 11 | 167,250 | 199,125 | 10 months | Suspension (2, 6–7, 29–32 W) |
Neutropenia, Elevated transaminases |
Right ear | No change | Moderate |
CMV cytomegalovirus, GCV ganciclovir, VGCV valganciclovir; * < LoD (IU/): lower than limit of detection; §N.A. not available
†Neurodevelopment level was defined according to the developmental quotient (DQ) as follows: no delay, > 75, mild 50–75, moderate